Jounce Therapeutics considers listing ($75m)

US (Massachusetts)-based startup Jounce Therapeutics could be listed as early as this year and raise at least $75m in funding. The company’s management submitted an application to the competent authorities some days ago, without specifying a timetable for completing the offer. Jounce was founded 4 years ago by VC Third Rock Ventures and focuses on the promising area of immunotherapy targeting solid tumors. It has recently received over $225m in funding from Celgene Corp., in order to develop new treatments which could fetch the recently-established startup up to $2.3bn. (Source The Boston Globe)